Pacira BioSciences director Gary Pace to retire June 30; consulting deal; shareholder votes

Pacira BioSciences, Inc.

Director Gary Pace to retire from Board June 30, 2024; no disagreement with company.
Consulting agreement amendment: one-year term from July 2024 to June 2025, $3,200/quarter for up to 8 hours.
Shareholders elected Class I directors: Laura Brege, Mark Froimson, Mark Kronenfeld, Michael Yang.
KPMG ratified as independent auditor for FY 2024 with ~43.9M for, 0.2M against.
Advisory say-on-pay vote passed with ~37.2M for, 4.1M against, 2.7M broker non-votes.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gary Pace

Director

PCRX · Pacira BioSciences, Inc.

Effective: 2024-06-30
Filed: June 13, 2024, 7:59 PM ET

On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Pace departed as Director at Pacira BioSciences, Inc..

Action: retire
Role: Director

Exact text from the filing

On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.

View on SEC.gov

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-24-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.